Loading
Latest filing published 19 Dec 2022 for Indaptus Therapeutics, Inc., €184.
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Boyan Vesselinov Litchev on record concern Indaptus Therapeutics, Inc. Over a trading history stretching from 31 January 2022 to 1 December 2022, the count stands at 4 filings.
No open-market sale appears; the market trades are 4 purchases worth €2,391. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
A typical purchase (the median) is worth €655. Clusters matter here: 2 out of 4 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 4 purchases with a full 90-day history, the hit rate stands at 100% and the median 90-day move at +1.8%. This is a record of the past, not a forecast.
The record was last updated on 19 December 2022 with an open-market purchase (€184) in Indaptus Therapeutics, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations